Down syndrome (DS) children have a unique genetic susceptibility to develop leukemia, in particular, acute megakaryocytic leukemia (AMkL) associated with somatic GATA1 mutations.
INTRODUCTION
Down syndrome (DS) children have an estimated 10-20-fold increased risk of developing acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) compared to non-DS children [1] and overall represent approximately 2% and 15% of childhood ALL and AML cases, respectively. The majority of DS AML cases (>90%) are the acute megakaryocytic phenotype (AMkL). It is estimated that DS children have a 500-fold increased risk of developing AMkL compared to non-DS children, highlighting a unique predisposition to develop a specific leukemia phenotype [2] . A variant of AMkL, the transient myeloproliferative disorder (TMD) is diagnosed in DS neonates with blast cells that display the same morphologic and immunophenotypic characteristics of AMkL [3] . The majority of TMD cases resolve spontaneously, though ~20% of infants will subsequently develop AMkL, requiring chemotherapy treatment.
A seminal finding from the laboratory of Dr. John Crispino [4] and subsequently confirmed by other groups was the occurrence of acquired somatic mutations at exon 2 of the transcription factor gene GATA1 (localized to Xp11.23) with nearly 100% penetrance in DS TMD and AMkL cases [4] [5] [6] [7] [8] [9] [10] . The reported sequence alterations in the region encoding the N-terminal activation domain of GATA1 included insertion, deletion, missense, nonsense and splice site mutations at the exon 2/intron boundary that invariably result in the synthesis of a short form GATA1 protein (GATA1s, 40-kDa protein compared to the 50-kDa wild-type protein) with altered transactivation capacity [4] . These mutations are believed to result in accumulation of poorly differentiated megakaryocytic precursors and represent initiating "genetic hits" in a multi-step process of leukemogenesis. The observation that these mutations occur exclusively in DS children with TMD/AMkL, suggests the possibility that trisomy 21 induces a "mutator phenotype". The prenatal presence of the GATA1 mutations establishes that genomic instability precedes leukemia, and further supports the hypothesis that DS may induce a mutator phenotype [10, 11] . This is supported by additional observations including reports that up to 18% of DS children with ALL have somatic mutations in a highly conserved region of the JAK2 gene [12] and DS individuals have atypical background somatic mutations at the hypoxanthine phosphoribosyl transferase locus [13] .
Analyzing the mutational spectrum of DS could provide critical insight into mechanisms of mutagenesis that may account for the significantly increased risk of this group to develop leukemia.
To date, no studies have analyzed the mutation spectrum of sequence alterations at GATA1/exon2 in DS TMD/AMkL cases. In this report, our analysis of the mutational spectrum at GATA1 in DS suggests that uracil accumulation, oxidative stress and reduced DNA base excision repair capacity may account for the generation of mutations as early leukemogenic events leading to the development of leukemia in DS children.
METHODS

Clinical TMD and AMkL Samples
Diagnostic blast cells from DS children with AMkL (n=14) and TMD (n=5) and from non-DS children with AMkL (n=13) were obtained from the Children's Hospital of Michigan leukemia cell bank and from the Pediatric Oncology Group 9421 study, as previously described [14, 15] . The diagnosis of AMkL was confirmed by flow cytometric detection of the megakaryocytic antigens, CD41 and CD61. Mononuclear cells were isolated on Ficoll-Hypaque gradients to obtain highly purified mononuclear cell fractions consisting mostly of leukemic blasts (median 66% and 81.5% in the DS and non-DS samples, respectively). DNA was isolated as described previously [14] . Blast cells were screened for the presence of GATA1 exon 2 mutations in genomic DNAs using forward (5'-GAGGGGGAAAGGAGGGAAGAGGAGCAGGTG-3') and reverse (5'-CACTCAGCCAATGCCAAGACAGCCACTCAATG-3') primers. Amplicons were sequenced directly and after subcloning in pGEM-T-Easy vector (Promega, Madison, WI). Sequence comparisons and translation analyses were performed using programs available from the National Center for Biotechnology Information (NCBI). Total RNAs were extracted from the samples using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA) per manufacturer protocol [14] . cDNAs were synthesized from 2 μ g RNA using random hexamer primers and an RT-PCR kit (Perkin Elmer), and purified with the QIAquick PCR Purification Kit (Qiagen, Valencia, CA). The research protocol was approved by the Human Investigation Committee of Wayne State University School of Medicine.
Sequence Analysis of GATA1 exon2 Mutations in the Literature.
GATA1 exon 2 mutations reported in the literature (Xu et al. [9] , Hitzler et al. [6] , Rainis et al.
[7], Wechsler et al. [4] , Mundschau et al. [5] , Groet et al. [8] , were compiled and analyzed along with the mutations identified in our patient samples to expand the number of mutations being analyzed.
Following the initial description of GATA1 exon 2 mutations (Wechsler et al. [4] ), the mutations were numbered from the initiating ATG in exon 2. The numbering systems used in other reports, were modified to be consistent for easier identification of specific sites within exon 2. In Rainis et al. [7] , Groet et al. [8] , and Hitzler et al. [6] , the adenine of the ATG which was identified as base 1 was modified to be base 113, while in Xu et al, [9] , the numbering begins at the 5' end of exon 2, 19 basepairs from our start site.
Fetal Liver Tissue
Fetal liver samples (17-23 weeks gestation) from 5 DS and 7 non-DS fetuses were obtained from therapeutically terminated pregnancies. Total RNAs were isolated from the fetal liver using the VersaGene RNA isolation system (Gentra) per the manufacturer's protocol. The use of fetal tissue was approved by the Human Investigation Committee of Wayne State University School of Medicine. Data was expressed as machine counts per microgram of protein.
Gene Expression by Real-time PCR
F2 Isoprostane detection
F 2 -isoprostanes were measured in fetal liver tissue using gas chromatography-mass spectrometry methods as previously described [18] . Briefly, tissue was homogenized in chloroform:methanol containing butylated hydroxytoluene BHT (0.005%) to prevent auto-oxidation, dried under a stream of nitrogen and resuspended in methanol containing BHT. Esterified F 2isoprostanes in phospholipids were saponified with potassium hydroxide. Samples were acidified, diluted with water, deuterated and an internal standard was added to the mixture. The mixture was then run on a silica column to separate isoprostanes from bulk fatty acids. The eluate was converted to pentafluorobenzyl esters by treatment with pentafluorobenzyl bromide to improve separation by gas chromatography. The mixture was than subjected to thin layer chromatography to remove excess pentafluorobenzyl bromide and unreacted fatty acids. The F 2 -isoprostane fraction was extracted with ethyl acetate and analyzed by injection into a Thermo Finnigan TRACE DSQ single quadrupole mass spectrometer. Peak height was used for quantification and data were corrected with the internal standard expressed as nanogram of F 2 -isoprostane per gram tissue.
Statistical Analysis
Differences in transcript levels and oxidative stress markers between different AML patient groups and in fetal tissues were compared using the nonparametric Mann-Whitney two-sample test.
Statistical analyses were performed with GraphPad Prism 4.0.
RESULTS AND DISCUSSION
Mutational Specificity of DS:
Because GATA1 mutations are specifically linked to both the TMD and AMkL phenotypes in individuals with DS, we evaluated the mutational spectrum at this locus in diagnostic blast cells from DS children with AMkL (n=14) and TMD (n=5) to provide insights into the sources of genomic instability in DS and potential mechanisms linked to increased risk of developing leukemia. Samples were screened for GATA1 mutations by PCR amplification of exon 2 followed by direct sequencing and/or subcloning and sequencing at least 10 clones per samples. As reported previously [15] , mutations at GATA1/exon 2 were detected in DS TMD and AMkL samples ( Table 1) , but not in non-DS AML samples, non-AMkL DS AML samples and DS ALL samples (data not shown). Table 1 summarizes the spectrum of GATA1 mutations and the sequence characteristics of the exon 2. The net effect of the mutations is the introduction of early stop codons and the synthesis of a shorter GATA1
(designed GATA1s, 40-kDa), initiated from a downstream translation start site and distinguishable from the wild-type GATA1 (50-kDa). Both GATA1s and the wild-type GATA1 show similar DNA binding abilities and interact with a partner protein named "friend of GATA1" (FOG1), though
GATA1s protein exhibits altered transactivation capacity due to the loss of the N-terminal activation domain [4] . Based on the presence of multiple mutations in several patient samples, a total of 23 distinct mutations from 19 patients were identified and analyzed. One DS patient developed AMkL (#7) following the spontaneous remission of TMD (#1) and blast samples from both conditions were analyzed and found to harbor the same GATA1 mutation. Of the 23 GATA1 mutations identified in the TMD and AMkL samples, 17 were insertion/deletion/duplication mutations (74%) and 6 were base substitutions (26%). Both single base changes and small insertions/deletions in exon 2 of GATA1 were described in previous studies [4] [5] [6] [7] [8] [9] . Figure 1 provides a schematic of the mutations and the sequence context of the mutations.
Insertions/Deletions/Duplications:
Insertion/deletion/duplication (ins/del/dup) mutations represent the predominant mutational signature of DS. This is consistent with the reported frequencies of ins/del/dup mutations in GATA1/exon 2 from other laboratories (including 100% [4] , 83% [6] , 76% [7] , and 64% [9] ).
Ins/del/dup mutations frequently arise as a result of polymerase slippage and in response to single and double strand breaks in DNA [19, 20] , both of which are impacted by local sequence context. Table 1 summarizes the ins/del/dup events in GATA1/exon 2 and indicates sequence elements that may contribute to the mutagenesis. A compilation of these mutations (including those reported in this work)
can be found in Table 2 . The list of published mutations are in order, starting from the ATG as described above, for a total of 85 ins/del/dup mutations across studies. Table 3 lists a summary of the sequence elements surrounding these mutations. Twenty-seven (32%) of all mutations fell within mononucleotide repeat sequence. One factor impacting mutagenesis at mononucleotide repeat sites is loss of DNA base excision repair (BER) capacity [21] , suggesting a role for reduced DNA repair capacity in the mutagenesis of DS.
Other sequence elements that drive ins/del/dup mutations include repeat or symmetrical elements. Sixteen of the 23 mutations in our patient samples, involved these types of sequences: 8 direct repeats, 4 palindromes and 4 mononucleotide runs ( Table 1 , notable sequence elements).
Examining the symmetrical elements of all 85 mutations (Table 2) , regions between four short direct repeats were highly mutable across studies (Table 3) . Forty-nine mutations occurred in regions involving direct repeats (58% of all ins/del/dup mutations), and 25 of these mutations directly interrupted one of the direct repeat elements, pointing to DNA strand breaks as a source of mutagenesis. In a meta-analysis of clinically relevant ins/del mutations [22] , the authors showed that certain sequence motifs are statistically associated with ins/del mutagenesis and several of these motifs were found surrounding the mutations in exon 2. In our own samples, these included a DNA polymerase α frameshift hotspot (TCCCCC), an Ig heavy chain switch repeat hotspot (TGGGG), and a palindrome (CTGGGG/CCCCAG), between which one insertion and one duplication occurred. In the analysis of all studies, additional Ig heavy chain switch repeat hotspots (CCCCA, GGGGT) and a FragileX hotspot (CCG…CCG) were present. Thirty-seven mutations (accounting for those that may arise as a result of more than one of the hotspots) arise at known ins/del hotspot sites (44% of all ins/del/dup mutations).
Six tandem duplications were detected in our patient samples (23% of all our mutations). This is intriguing because uracil accumulation can generate tandem duplications through strand break intermediates [23] , providing evidence that uracil may be an initiating lesion in the mutagenesis of DS.
It is known that uracil incorporation in E. coli generates base substitutions (more below) as well as ins/del/dup mutations [24] . A specific tetramer, CTGG, was associated with ins/del/dup mutations in response to uracil accumulation in these studies. While the importance of this sequence is unclear, it is intriguing that our clinical samples demonstrated a similar sequence. Four of our observed mutations directly involved the CTGG site, and 5/6 duplications were in close proximity, suggesting a role for uracil in the mutagenesis of DS. Amongst the different studies, 16 duplication events (19% of all ins/del/dup mutations) could be definitively identified, and 13 of these occur in a 47 basepair fragment of exon 2. In addition, 16 more mutations within this short region may also be duplication events, as many reports list only "insertion" as the type of mutation without specifying whether the insertion is a duplication. This 47 basepair stretch is very cytosine-rich: 42.5% of all bases in this stretch are cytosine (even distribution would be 25% of all bases). Cytosine and/or CpG sites are involved in either the flanking sequence or the duplicated sequence in 16/16 duplication mutations. In every duplication event, cytosine and/or CpG sites are involved in either the flanking sequence or the duplicated sequence. Because deamination of cytosine yields uracil, which drives duplication events, these data support a role for uracil in initiation of duplication mutations in DS. Mechanistically, cytosine deamination increases to a rate 140-fold higher in single stranded DNA than in double strand DNA [25] and single strand DNA arises during transcription. GATA1 is an actively transcribed gene, increasing the presence of single stranded DNA and the likelihood of cytosine deamination.
The four sequence elements discussed (mononucleotide repeats, direct repeat sequence, indel hotspots, and cytosine-rich regions) potentially account for 72 of the 85 mutations. Although the sequence elements are important in permitting mutagenesis, the end product of this mutagenesis (GATA1s) may be the critical factor providing a selective growth advantage that drives leukemogenesis. The accumulation of mutations in exon 2 provides a locus to study the underlying mechanisms which lead to the generation of the mutations, which ultimately may account for the 500fold greater risk for DS children to develop AMkL.
Base Substitutions
A total of six base substitutions were identified in our patient population (Table 4A ). Half of the base substitutions (3/6) occurred in patients also expressing ins/del/dup mutations responsible for the generation of GATA1s, and these base substitutions would not generate GATA1s. Three patients expressed only base substitution mutations (patients 3, 8, 10), which would be expected to generate
GATA1s (Table 4A) , implicating these in the development of the leukemia phenotype. Analysis of the mutational specificity of the base substitutions revealed that of the six base substitutions identified, 4
were transition mutations and 2 were transversion mutations.
Oxidative Stress and Mutations
DS is characterized by increased oxidative stress secondary to increased copy number and expression of several key redox-related genes encoded on chromosome 21 [e.g. cystathionine-ßsynthase (CBS), zinc-copper superoxide dismutase (SOD1), amyloid precursor protein (APP)]. A signature mutation induced by oxidative stress is the G:C>T:A transversion. Two of six base substitutions were G:C>T:A transversions (Table 4A) , which may result from the increased oxidant load in DS. Table 4B summarizes the published base substitutions of GATA1 mutations in combination with our findings which indicate that the G:C>T:A transversion is the predominant base substitution observed in DS TMD and AMkL, consistent with oxidative stress as a potential significant contributor to mutagenesis in DS.
The other predominant base substitutions observed across studies (Tables 4A and 4B) (Table 4A ). Further, 14/26 base substitutions reported across studies (Table 4B) were represented by transitions, suggesting a role for uracil and altered folate metabolism in the mutagenesis of DS. Figure 2B ).
This finding is striking, as we have previously demonstrated that a 50% reduction in β -pol expression predisposes mice to cancer [17] . Further, these findings confirm previous reports of reduced Figure 3D ). Collectively, these data support the hypothesis that reduced DNA repair capacity in the DS prenatal environment predisposes to mutagenesis.
Oxidative Stress in DS:
More than 20 genes involved in oxidative metabolism are localized to chromosome 21, including SOD1 and CBS. Accordingly, increased levels of oxidative stress are reported for individuals with DS for a variety of oxidation parameters, including lipid peroxidation, protein oxidation and DNA oxidation [36] [37] [38] [39] [40] . Recently Perrone et al. reported that amniotic fluid in DSdiagnosed pregnancies exhibited a 9-fold increase in isoprostane levels as compared to non-DS pregnancies [41] . Based on these observations, the analysis of the prenatal environment vis-à-vis oxidative stress in fetal hematopoietic tissue was also performed in 3 DS fetal livers and 7 non-DS fetal livers in which there was sufficient tissue for analysis. Isoprostanes accumulate as a result of free radical attack on membrane phospholipids, and are a marker of lipid peroxidation. To determine the extent of lipid peroxidation in fetal livers from DS and non-DS pregnancies, levels of F2-isoprostane were measured. There was no difference in median F2 isoprostane levels in the DS (11.25/g tissue) compared to non-DS fetal tissues (11.25/ g tissue) ( Figure 3E ). It is possible that other measures of oxidative stress (e.g. DNA 8-hydroxydeoxyguanosine) may be more informative as well as an analysis of a greater number of samples, to better define the role of oxidative stress in the generation of G:C>T:A mutations, a signature mutation of oxidative stress.
CBS and SOD -Driven Model of Genomic Instability in DS
We propose a model to explain the mutational spectrum of DS as a function of CBS activity.
CBS catalyzes the irreversible condensation of serine and homocysteine to form cystathionine, which directs homocysteine toward cystathionine synthesis and away from methionine remethylation, creating a folate trap and thymidylate imbalance (Figure 4) . The latter will result in uracil misincorporation into DNA. Left unrepaired, uracil will initiate a pattern of G:C>A:T, A:T>G:C and insertion/deletion/duplication mutations, as seen in our analyses. The impact of CBS is greater than can be explained by the DS "gene dosage" effect (1.5-fold) alone, based on our earlier finding that CBS transcripts are a median 12-fold higher in DS AMkL blasts than in AML blasts from non-DS children [42] . This suggests an adaptive response by CBS to the increased ROS environment in DS. Reports in the literature support a role for CBS as a key factor driving metabolic flux in response to oxidative stress, and establish that both oxidative stress and DS amplify CBS activity [43] [44] [45] [46] [47] [48] . Our model hypothesizes that the increased copy number of SOD in trisomy 21 will drive increased H 2 O 2 production that is quenched by glutathione peroxidase. One impact of increased H 2 O 2 production is the oxidation of DNA 8-hydroxydeoxyguanosine (8-OHdG) which becomes fixed as G:C>T:A mutations when DNA repair capacity is compromised. The effects of CBS in trisomy 21 cells accommodate the pro-oxidant effects of trisomy 21 by accelerating glutathione production and causing a corresponding trap of folate in its fully reduced form, a biochemical dead-end. We propose this mechanism is the source of mutagenesis in DS that generates GATA1 mutations as an early initiating step in the process of leukemogenesis. Based on our data, we hypothesize that oxidative stress, uracil accumulation, and reduced DNA repair capacity all interact to generate the mutations observed in GATA1 exon 2 of DS TMD and AMkL cases. Oxidative stress can damage DNA bases and oxidize nucleotide pools, accounting for G:C>T:A mutagenesis. It can also drive glutathione production, thereby diverting metabolic intermediates away from folate metabolism, creating a functional folate deficiency that in turn would drive uracil accumulation in the DNA. Evidence for abnormal folate metabolism in DS includes: i) excessive systemic toxicity (myelosuppression, mucositis, hepatotoxicity) in DS children with ALL treated with the antifolate methotrexate [50, 51] ; ii) decreased methotrexate toxicity in DS lymphocytes accompanying administration of folic acid in vivo or in vitro [52] ; and iii) the increased methotrexate toxicity observed when folate is deficient [53] . The DNA damage induced by oxidative stress and uracil incorporation in DNA is processed by the BER pathway, and we provide evidence for a BER defect in DS, suggesting that this defect is a critical factor driving the mutator phenotype of DS.
CONCLUSIONS
Reduced repair capacity in the face of increasing DNA damage will drive increased rates of mutagenesis.
Our study is the first to examine possible mechanisms of mutagenesis in DS tissues including the fetal liver, which may lead to the generation of GATA1 mutations. Several recent studies identified that erythro-megakaryocytic progenitor frequency was increased in DS fetal livers compared to gestation-matched non-DS control samples [54] and megakaryocyte hyperproliferation was detected in the fetal liver of a DS fetus with hydrops fetalis in the absence of GATA1 mutations [54, 55] ,
indicating that abnormal hematopoiesis occurs in the DS fetal liver with the background of constitutional trisomy 21. Hence, DS fetal liver cells appear to be primed for the acquisition of GATA1 mutations as early steps in the development of TMD and/or AMkL.
One limitation of our study was the availability of number and quantity of fetal liver samples and planned future studies will be performed on hematopoietic progenitor cells (e.g. CD 34+) isolated from freshly obtained tissue as opposed to cryopreserved tissue.
We propose mechanisms linking chromosome 21-localized genes (CBS and SOD1) to the generation of mutations in the GATA1 gene, as an early or initiating step in the DS leukemogenesis. Mutations are written as reported by the authors in the original reports, except that the numbering of the mutations was adapted to reflect a uniform numbering system as described in methodology. In addition, if a mutation was found to be a duplication that was not indicated in the original report(s), the designation (dup) follows the mutation. Several mutations from other reports have not been included because they occurred in regions outside exon 2. Figure 2 , with a superscript indicating the location within exon 2. In the right column, the mutations presented and enumerated in Table 3 Table 3 ) is indicated. In the middle column, the mutation is described. In the far right column duplicated sequences and important flanking sequences are indicated. The duplicated sequences are in upper case; mutations within the duplication are also in uppercase, but are also italicized; flanking sequences that are not part of the duplicated sequence are in lower case. 
B. Comparison of single nucleotide substitutions across studies.
A compilation of all base substitution mutations reported in previous studies [6, 7, 8, 9] are compared and added to the base substitution mutations found in this study. 
